You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
Cancer Genetics' stalking horse bid is subject to higher bids from competitors, and the highest bid will require court approval.
The company also said that its cash burn rate for Q2 is estimated to be about $4.8 million, or $1.3 million more than its average cash burn.
The deal makes Cancer Genetics' diagnostic testing services available to more than one million people in Harvard Pilgrim's provider network.
The partners will provide complex oncology genomic testing, core central laboratory analysis, project and data management, and sample logistics.
The company's stock failed to meet the exchange's $1 minimum bid requirement.
Over the next two years, Cancer Genetics' genomic laboratory in Hyderabad, India, expects to analyze several thousand samples provided by ReproCell.
An increase in test order volume was offset by lower reimbursement from both Medicare and third-party payors.
Revenue from SelectOne clinical trials services and acquisitions drove the year over year growth.
Once an oncologist decides a patient needs chemotherapy, Moffitt will test for PGx markers that might hinder his or her ability to metabolize anti-vomiting and pain meds.
The partners will study the association between genetic variants and chemotherapy side effects to find biomarkers for an upcoming NGS pharmacogenomics panel.
A German shepherd called Nala has had her genome sequenced.
A coronavirus serology test garners Emergency Use Authorization from the US Food and Drug Administration, but the Los Angeles Times asks: how will tests like that be used?
Certain gene variants in conjunction with a healthy lifestyle may keep brains young, according to New Scientist.
In Science this week: increased CD8 T cell density and increased IFN-gamma response may indicate metastatic prostate cancer patients who will respond to immune checkpoint blockade therapy.